WEBULL
News
AKBA
1.500
+7.91%
0.110
Weekly Report: what happened at AKBA last week (0202-0206)?
Weekly Report · 21h ago
Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views
Benzinga · 3d ago
Akebia Therapeutics Price Target Cut to $4.00/Share From $6.00 by Piper Sandler
Dow Jones · 3d ago
Akebia Therapeutics Is Maintained at Overweight by Piper Sandler
Dow Jones · 3d ago
Piper Sandler Maintains Overweight on Akebia Therapeutics, Lowers Price Target to $4
Benzinga · 3d ago
Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Akebia Therapeutics (AKBA) and Denali Therapeutics (DNLI)
TipRanks · 3d ago
Akebia Therapeutics Files Initial Beneficial Ownership Statement for Carolyn M. Rucci, SVP and Chief Legal Officer
Reuters · 6d ago
AKEBIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 02/02 21:05
Weekly Report: what happened at AKBA last week (0126-0130)?
Weekly Report · 02/02 09:46
Akebia Therapeutics Updates Executive Severance and Leadership Terms
TipRanks · 01/30 13:59
Weekly Report: what happened at AKBA last week (0119-0123)?
Weekly Report · 01/26 09:47
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Abeona Therapeutics (ABEO) and Akebia Therapeutics (AKBA)
TipRanks · 01/21 15:40
Weekly Report: what happened at AKBA last week (0112-0116)?
Weekly Report · 01/19 09:51
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
Seeking Alpha · 01/13 18:21
Akebia announces corporate updates, 2026 pipeline outlook
TipRanks · 01/12 13:52
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
TipRanks · 01/12 13:37
Akebia Therapeutics Announces AKB-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027
Benzinga · 01/12 13:14
AKEBIA THERAPEUTICS INC - AKB-097 PHASE 2 RARE KIDNEY DISEASE BASKET TRIAL SCHEDULED TO BEGIN IN 2H 2026 WITH INITIAL DATA EXPECTED IN 2027
Reuters · 01/12 13:02
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.